Eli Lilly announced on Thursday that it will submit regulatory applications for retatrutide, its next-generation obesity treatment, in the first quarter of 2027, moving its filing timeline later than previously planned. The company said the shift reflects the need to collect and verify additional manufacturing and quality-control data regulators require for review.
The weekly injectable retatrutide achieved positive results in two further Phase 3 trials, demonstrating both significant weight reduction and improvements in blood glucose control among adults with obesity and related conditions. In one of the trials, adults living with obesity and Type 2 diabetes experienced average weight losses of up to 20.8 percent, equivalent to nearly 50 pounds, at the 80-week mark. In the other trial, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6 percent of body weight, or about 55.8 pounds, at 80 weeks.
Regulatory and program status
Kenneth Custer, president of Lilly Cardiometabolic Health, said the company believes it has the clinical information necessary to pursue global approval for retatrutide as a potential treatment not only for obesity but also for knee osteoarthritis pain and obstructive sleep apnea. Despite that clinical readiness, Lilly indicated additional time is needed to finalize and validate manufacturing and quality-control materials before filing.
How the drug works and how it compares
Retatrutide acts on three hormone targets - GLP-1, GIP and glucagon - distinguishing it from therapies that engage only one or two of those pathways. For context on comparators: tirzepatide, the active ingredient in Lilly's marketed product Zepbound, mimics GLP-1 and GIP, while semaglutide, the active ingredient in Novo Nordisk's Wegovy, mimics only GLP-1.
Safety and tolerability
Commonly reported side effects in the trials included diarrhea, nausea and constipation. Lilly characterized these adverse events as consistent with findings from previous studies and aligned with the broader GLP-1 treatment class.
Commercial outlook and competitive context
Analysts at TD Cowen estimated in January that retatrutide could produce sales of $3.8 billion by 2030. Retatrutide is positioned as a follow-on pillar for Lilly's obesity franchise after Zepbound and the company's recently launched oral agent Foundayo.
Legal note
This week, Novo Nordisk filed a lawsuit against Lilly in U.S. District Court in New Jersey, alleging false advertising related to Lilly's weight-loss medications compared with Novo Nordisk's products.
As Lilly prepares the manufacturing and quality-control documentation needed for regulators, the company is balancing clinical success with the procedural requirements that precede formal submissions. The shift in filing timing underscores the emphasis regulators place on validated production data alongside clinical evidence.